Recurrent Endometrial Carcinoma Withdrawn Phase 2 Trials for DB00351 (Megestrol acetate)

IndicationStatusPhase
DBCOND0028796 (Recurrent Endometrial Carcinoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01943058Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial CancerTreatment